SynthesisBMC musculoskeletal disorders2023

The use of metformin, sulfonylurea compounds and insulin and the risk of hip fractures in diabetic patients: a systematic review and meta-analysis of observational studies.

What the trial testedas reported · 631,297 people · 2023

Not counted

−17%−24% to −9%

Bigger than 5 in 10 for adverse events & safety

As reported

HR 0.833, 95% CI 0.76–0.91

Not counted

+18%+7% to +29%

Bigger than 4 in 10 for adverse events & safety

As reported

HR 1.175, 95% CI 1.07–1.29

the abstract, start to end

… reduced the risk of hip fracture (HR: 0.833, 95% CI: 0.759, 0.914, …

(HR: 1.175, 95% CI:1.068,1.293, P:0.001), …

← favours treatmentfavours comparator →

could be chance

Adverse events & safety

HR 0.8330.76–0.91

Adverse events & safety

HR 1.1751.07–1.29

MetforminInsulinAdverse events & safety

1 / 3

2023

2024

2025

2026

this papercites it